Afatinib as first-line treatment in patients with -mutated non-small cell lung cancer in routine clinical practice
Autor: | Wolfgang M. Brückl, Martin Reck, Frank Griesinger, Harald Schäfer, Cornelius Kortsik, Tobias Gaska, Justyna Rawluk, Stefan Krüger, Konrad Kokowski, Stephan Budweiser, Joachim H. Ficker, Christopher Hoffmann, Andrea Schüler, Eckart Laack |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: | |
Zdroj: | Therapeutic Advances in Medical Oncology, Vol 13 (2021) |
Druh dokumentu: | article |
ISSN: | 1758-8359 17588359 |
DOI: | 10.1177/17588359211012361 |
Popis: | Background: Lung cancer is a leading cause of cancer-related death in Germany and worldwide. Non-small cell lung cancer (NSCLC) comprises ~80% of lung cancer diagnoses; in White patients, around 10% of NSCLC cases are epidermal growth factor receptor mutation-positive ( EGFR m+). Head-to-head clinical trials have demonstrated superior efficacy with second-/third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) versus first-generation EGFR TKIs in EGFR m+ NSCLC. Data from routine clinical practice are necessary to confirm that clinical trial findings are transferable to real-world populations. Methods: In NCT02047903, a prospective non-interventional study in Germany, patients with EGFR m+ NSCLC received first-line afatinib until disease progression or intolerable adverse events. Key objectives were progression-free survival (PFS) rate at 12 months, objective response rate (ORR) and overall survival (OS). Safety/tolerability was also assessed. Results: Of 152 patients, 106 (69.7%) were female, 20 (13.1%) patients had an uncommon EGFR mutation and 51 patients (33.6%) had brain metastases. A starting dose of |
Databáze: | Directory of Open Access Journals |
Externí odkaz: |